Clinical evidence of autologous graft versus tumor effect

American Journal of Immunology

Volumn 5, Issue 1, 2009, Pages 1-7

  Porrata, Luis F ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Absolute lymphocyte count; Autologous graft versus tumor effect; Autologous hematopoietic stem cell transplantation; Malignancies; Survival

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; PLERIXAFOR;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; APHERESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CONVALESCENCE; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; LYMPHOBLASTOMA; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFUSION; LYMPHOCYTOPENIA; MEDICAL LITERATURE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; REVIEW; STEM CELL MOBILIZATION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 70249103866     PISSN: 1553619X     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajisp.2009.1.7     Document Type: Review

References (42)

1. Appelbaum, F.R., 2001. Hematopoietic cell transplantation as immunotherapy. Nature, 411: 385-389.
2. Porrata, L.F. and S.N. Markovic, 2004. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin. Exp. Med., 4: 78-85. http://www.ncbi.nlm.nih.gov/ pubmed/15672944
3. Barnes, D.W.H., M.J. Corp, J.F. Loutit and F.E. Neal, 1956 Treatment of murine leukemia with x-rays and homologous bone marrow. Preliminary communication. Br. Med. J., 2: 626-627. http://www.pubmedcentral.nih.gov/ articlerender.fcgi?tool=pubmed&pubmedid=13356034
4. Mathe, G., J.L. Amiel, L. Schwarzenberg, L. Cattan and M. Schneider, 1965. Adoptive immunotherapy of acute leukemias: Experimental and clinical results. Cancer Res., 25: 1525-1531. http://www.ncbi.nlm.nih.gov/pubmed/5323965
5. Ruggeri, L., M. Capanni and E. Urbani et al., 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 295: 2097-2100 http://www.ncbi.nlm.nih.gov/pubmed/ 11896281.
6. Truitt, R.L. and A.A. Atasoyly, 1991. Contribution of CD4+ and CD8+ T cells to graft-versus-host and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplantat., 8: 51-58. http://www.ncbi.nlm.nih.gov/pubmed/1833016
7. Palathumpat, V., S. Dejbakhsh-Jones and S. Strober, 1995. The role of purified CD8+ in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation, 60: 355-361. http://www.ncbi.nlm.nih.gov/pubmed/7652765
8. Porter, D.L., 2001. The graft-versus-tumor potential of allogeneic cell therapy: An update on donor leukocyte infusions and non-myeloablative allogeneic stem cell transplantation. J. Hematother. Stem Cells Res., 10: 465-480. http://www.ncbi.nlm.nih.gov/pubmed/11522230
9. Slavin, S., 2001. Immunotherapy of cancer with alloreactive lymphocytes. Lancet, 2: 491-495. http://www.ncbi.nlm.nih.gov/pubmed/11905725
10. Kolb, H.J., A. Schattenberg, J.M. Goldman, B. Hertenstein and N. Jacobsen et al., 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86: 2041-2050. http://www.ncbi.nlm.nih.gov/pubmed/7655033
11. Slavin, S., S. Morecki, L. Weiss and R. Or, 2003. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Crit. Rev. Oncol./Hematol., 46: 139-163. http://www.ncbi.nlm.nih.gov/pubmed/12711359
12. Slavin, S., A. Nagler, E. Naparstek, Y. Kapelushnik and M. Aker et al., 1998. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological disease. Blood, 91: 756-763. http://www.ncbi.nlm.nih.gov/pubmed/9446633
13. Hogan, W.J. and R. Storb, 2003. Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease. Immunol. Res., 28: 1-11. http://www.ncbi.nlm.nih.gov/pubmed/ 12947220
14. Powles, R., S. Singhal, J. Treleaven, S. Kulkarni, C. Horton and J. Mehta, 1998. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood, 91: 3481-3486. http://bloodjournal.hematologylibrary.org/cgi/content/short/91/9/3481
15. Pavletic, Z.S., S.S. Joshi, S.J. Pirruccello, S.R. Tarantolo and J. Kollalth et al., 1998. Lymphoid reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant., 21: 33-41.
16. Porrata, L.F., M.A. Gertz, D.J. Inwards, M.R. Litzow and M.Q. Lacy et al., 2001. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood, 98: 579-585. http://cat.inist.fr/ ?aModele=afficheN&cpsidt=1052912
17. Porrata, L.F., M.R. Litzow, A. Tefferi, L. Letendre and S. Kumar et al., 2002. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia, 16: 1311-1318. http://www.nature.com/leu/journal/v16/n7/full/2402503a.html
18. Porrata, L.F., D.J. Inwards, I.N. Micallef, S.M. Ansell, S.M. Geyer and S.N. Markovic, 2002. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br. J. Haematol., 117: 629-633. http://www.ncbi.nlm.nih.gov/pubmed/12028034
19. Porrata, L.F., J.N. Ingle, M.R. Litzow, S.M. Geyer and S.N. Markovic, 2001. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant., 28: 865-871. http://www.nature.com/bmt/journal/v28/n9/full/1703236a.html
20. Porrata, G.M.A., M.R. Litzow, M.Q. Lacy, A. Dispenzieri and D.J. Inwards et al., 2005. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin. Can. Res., 11: 1210-1218. http://cat.inist.fr/?aModele=afficheN&cpsidt=16465932
21. Gordan, L.N., M.W. Surgue, J.W. Lynch and K.D. Williams et al., 2003. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant., 31: 1009-1013. DOI: 10.1038/sj.bmt.1704050
22. Kim, H., H.J. Sohn, S.E. Kim, H.J. Kang, S. Park and S. Kim et al., 2004. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant., 34: 43-49. http://cat.inist.fr/?aModele=afficheN&cpsidt=15915790
23. Nieto, Y., E.J. Shpall, I.K. McNiece, S. Nawaz and J. Beaudet et al., 2004. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clin. Can. Res., 10: 5076-5086. http://cat.inist.fr/ ?aModele=afficheN&cpsidt=16014624
24. Ackerstein, A., E. Kedar and S. Slavin, 1991. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model of control of minimal residual disease in malignant hematologic disorders. Blood, 78: 1212-1215. http://www.ncbi.nlm.nih.gov/ pubmed/1878588
25. Mielcarck, M. and R. Storb, 2003. Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematopoietic malignancies. Cancer Treat. Rev., 29: 283-290. http://www.journals.elsevierhealth.com/ periodicals/yctrv/article/PIIS0305737203000045/abstract
26. Peggs, K.S. and S. Mackinnon, 2001. Cellular therapy: Donor lymphocyte infusion. Curr. Opin. Hematol., 8: 349-354. http://www.ncbi.nlm.nih.gov/ pubmed/11604574
27. Yoong, Y., L.F. Porrata, D.J. Inwards, S.M. Ansell and I.N. Micallef et al., 2005. The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma. Leukemia Lymphoma, 46: 1287-1294. http://cat.inist.fr/?aModele=afficheN&cpsidt=17043213
28. Porrata, L.F., D.J. Inwards, M.Q. Lacy and S.N. Markovic, 2001. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-α in autologous stem cell transplantation. Bone Marrow Trnasplant., 28: 673-680. http://www.nature.com/bmt/journal/v28/n7/abs/1703203a.html
29. Lotzova, E., C.A. Savary and R.E. Champlin, 1993. Genesis of human oncolytic natural killer cells from primitive CD34+CD33-bone marrow progenitors. J. Immunol., 150: 5263-5269. http://cat.inist.fr/ ?aModele=afficheN&cpsidt=4832411
30. Miller, J.S., C. Verfaillie and P. McGlave, 1992. The generation of human natural killer cells from CD34+/DR-primitive progenitors in long-term bone marrow culture. Blood, 80: 2182-2187. http://www.ncbi.nlm.nih.gov/pubmed/1384796
31. Porrata, L.F., D.J. Inwards, S.M. Ansell and I.N. Micallef et al., 2008. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: A prospective study. Biol, Blood Marrow Transplant., 14: 807-816. DOI: 10.1016/j.bbmt.2008.04.013
32. Porrata, L.F., M.R. Litzow, D.J. Inwards and D.A. Gastineau et al., 2004. Infused peripheral blood autograft absolute lymphocyte count correlates with day 14 absolute lymphocyte count and clinical outcome after autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant., 33: 291-298. DOI: 10.1038/sj.bmt.1704355
33. Porrata, L.F., M.A. Gertz, S.M. Geyer, M.R. Litzow and D.A. Gastineau et al., 2004. The dose of infused lymphocytes in the autograft directly correlates with clinical outcomes after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia, 18: 1085-1092. DOI: 10.1038/sj.leu.2403341
34. Symeonidis, A., S. Ings, N. Rabin, M. Watts and S. D'Sa et al., 2007. Patients with multiple myeloma, transplanted with lymphocyte-rich peripheral blood autografts have more favorable outcome. Haematologica, 92: PO-822. http://online.haematologica.org/Kos/ browserecord.php?-action=browse&-recid=411
35. Hiwase, D.K., S. Hiwase, M. Bailey, G. Bollard and A.P. Schwarer, 2008. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant., 14: 116-124. http://www.ncbi.nlm.nih.gov/ pubmed/18158968
36. Porrata, L.F., M.R. Litzow and S.N. Markovic, 2005. Graft engineering for autologous stem cell transplantation. Gene Ther. Mol. Biol., 9: 121-134. http://www.gtmb.org/VOL9B/GTMBVOL6BPDF/INDIVIDUAL/ 14._Porrata.pdf
37. Lapport, G.G., B.L. Levine, E.A. Stadtmauer and S.J. Schuster et al., 2003. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood, 102: 2004-2013. http://www.ncbi.nlm.nih.gov/pubmed/12763934
38. Rapoport, A.P., E.A. Stadtmauer, B.L. Levine, A. Badros and G. Akpek et al., 2004. Adoptive transfer of ex vivo costimulated autologous T-cells after autotransplantation for Myeloma (MM) accelerates post-transplant T-cell recovery. Biol. Blood Marrow, 10: 22-22. DOI: 10.1016/j.bbmt.2003.12.089
39. Rapoport, A.P., B.L. Levine, A. Badros, B. Meisenberg and K. Ruehle et al., 2004. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant., 33: 53-60. http://www.ncbi.nlm.nih.gov/pubmed/ 14578928
40. Hiwase, D.K., S. Hiwase, M. bailey, G. Bollard and A.P. Schwarer, 2008. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Cytotherapy, 10: 507-517. http://www.ncbi.nlm.nih.gov/pubmed/18608354
41. Holtan, S.G., L.F. Porrata, I.N. Micallef, D.J. Padley and D.J. Inwards et al., 2007. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin. Lymphoma Myeloma, 7: 315-318. http://www.ncbi.nlm.nih.gov/pubmed/17324341
42. Katipamula, R., L.F. Porrata, D.A. Gastineau, and Greiner C S.N. Markovic et al., 2005. Effect of apheresis instrumentation observed on survival following autologous hematopoietic stem cell transplantation for non-Hodgkin's. Bone Marrow Transplant., 37: 811-7. DOI: 10.1038/sj.bmt.1705338